QIAGEN and Blirt

Go to content

QIAGEN and Blirt

Wardyński & Partners provided comprehensive advice to QIAGEN N.V. on its acquisition of a 96% stake of shares in BLIRT S.A. (listed on the NewConnect market in Warsaw). Both companies operate in the molecular research industry.

The work of the firm’s lawyers was led by Marcin Pietkiewicz and Maciej A. Szewczyk. Katarzyna Jaroszyńska and Bartosz Lewandowski were also key members of the team.

QIAGEN N.V., a Netherlands-based holding company, is a leading global provider of solutions enabling customers to gain valuable insights from molecular samples. QIAGEN’s technologies analyse DNA, RNA and proteins from blood, tissue and other materials, and interpret the results based on bioinformatics software and knowledge bases. QIAGEN provides solutions to more than 500,000 customers around the world in molecular diagnostics, forensics, pharma, biotech, and life sciences research. As of 31 March 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide.

BLIRT S.A. is a Polish company specialising in industrial-scale production of high-quality recombinant proteins. The firm also produces easy-to-use kits for isolation of DNA and RNA, as well as reagents for reverse transcription and real-time PCR. All key enzymes and kits are independently manufactured by the company to ensure repeatability and the highest product quality. The company employs nearly 90 people, including 49 members of the research and manufacturing team, 15 of whom hold a doctorate in molecular biology, biotechnology, biochemistry or organic chemistry. BLIRT has four labs outfitted with top-quality equipment, including two with lines for industrial-scale manufacturing.